Pharmacies must pay $650.6 million to Ohio counties in opioid case

Pharmacies must pay 0.6 million to Ohio counties in opioid case


A customer views merchandise for sale at a Walgreens store in the Hollywood neighborhood of Los Angeles.

Christopher Lee | Bloomberg | Getty Images

Pharmacy operators CVS, Walmart and Walgreens must pay a combined $650.6 million to two Ohio counties to address the damage done by the opioid epidemic, a federal judge ruled on Wednesday.

The order by U.S. Judge Dan Polster in Cleveland comes after a jury last November concluded that the pharmacy chains helped create a public nuisance in Lake and Trumbull counties by over-supplying addictive pain pills, many of which found their way onto the black market. The pharmacies have said they would appeal that verdict.

Polster held a separate non-jury trial earlier this year to decide how much the companies had to pay.

“We are disappointed with this outcome,” Walgreens spokesman Fraser Engleman said in a statement. “The facts and the law did not support the jury verdict last fall, and they do not support the court’s decision now.”

CVS and Walmart did not immediately respond to requests for comment.

Polster said the sum must be paid over 15 years, with the amount for the first two years, or $86.7 million, to be paid into a fund immediately. The judge also ordered the companies to implement new procedures to combat illegal diversion of opioid drugs.

The U.S. opioid epidemic has caused more than 500,000 overdose deaths over two decades, according to government data. More than 3,300 opioid lawsuits have been filed nationally against drugmakers, distributors and pharmacy chains.

The litigation has resulted in several nationwide settlements, including a $26 billion deal with Johnson & Johnson and the three leading distributors, a $2.37 billion settlement with AbbVie Inc and a $4.25 billion settlement with Teva Pharmaceutical Industries Ltd.

Pharmacies have yet to reach a nationwide settlement.



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More